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PRÁTICA CLINICA
and the statements on safety, pharmacovigilance and
traceability are in accordance with the previous position
paper.
Keywords: Ankylosing spondylitis; Biosimilar; Anti-tu-
mor necrosis factor-alpha therapy; Rheumatoid arthritis.
IntroductIon
Biosimilars are biological medicinal products contain-
ing a version of the active substance of an already au-
thorized original biological medicinal product (refe -
rence product)1, for which they are required to have
similar efficacy, safety and immunogenicity. Biosimilars
were created for the sole purpose of mitigating the eco-
nomic burden put on healthcare systems by biological
therapies, which are currently the main driver for direct
costs with rheumatic patients - in 2014, these drugs
represented four of the five top selling drugs in the
world with a combined value of US$38.9 billion in
sales2. Importantly, biosimilar-related savings could hy-
pothetically increase the number of patients treated
with biologicals, allow an earlier initiation of biological
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AbstrAct
Biosimilars are new and more affordable similar ver-
sions of previously approved reference biological drugs.
Following the approval of the first monoclonal anti-
body biosimilar in 2013, the Portuguese Society of
Rheumatology issued a position paper on the use of
biosimilars in rheumatic conditions covering efficacy,
safety, extrapolation, interchangeability, substitution
and pharmacovigilance. However, as this is a rapidly
evolving field, it was felt that the knowledge and evi-
dence gathered since then justified an update of these
statements. Literature searches on these issues were
performed and the search results were presented and
discussed in a national meeting. Portuguese rheuma-
tologists considered that affordability should be taken
into consideration when initiating a biological drug,
but other factors were equally important. In patients
already on reference biological treatment, switch to a
more affordable biosimilar is desirable, provided a set
of conditions is rigorously met. Automatic substitution
is not acceptable and current evidence is insufficient to
support interchangeability. Extrapolation of clinical in-
dications is endorsed by Portuguese rheumatologists,
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therapies upon conventional drug failure and possibly
mitigate inequities in treatment access between low
and high-income countries2,3.
Biosimilars are, by definition, similar but not iden-
tical to their reference products. As opposed to gene -
rics, it is not possible for biosimilar developers to pro-
duce an exact copy of the originator drug due to its in-
tricate molecular structure and to the inherent, yet
controlled, variability associated with specificities in
the manufacturing processes4. The development of a
biosimilar candidate is a highly regulated process with
rigorous analytical, preclinical and clinical testing and
an extensive body-of-evidence required before drug
approval5. Until January 2017, twenty-three biosimi-
lars were granted marketing authorization by the Eu-
ropean Medicines Agency (EMA), making the Euro-
pean market the most experienced in biosimilar regu-
lation and approval6. Up to 2013, all approved biosimi -
lars were hormones and growth factors, with simpler
chemical structures and lower molecular weights (the
first, somatropin [Omnitrope®], was approved in
2006). In 2013, the marketing of the first infliximab
(INF) biosimilar (CT-P13, Remsima®/Inflectra®) raised
lively debate among physicians due to the structural
complexity of monoclonal antibodies, much more dif-
ficult to replicate, and the fear of consequent unex-
pected events. The discussion around biosimilars
broadened to all healthcare stakeholders and focused
not only on clinical practice (immunogenicity, extra -
polation of clinical indications, interchanging and au-
tomatic substitution), but also on regulatory require-
ments (preclinical and clinical assessment standards
and proper pharmacovigilance) and ethical issues (fair
distribution of health resources and healthcare system
sustainability).
Soon after the endorsement of CT-P13 (Remsima®/
/Inflectra®), the Portuguese Society of Rheumatology
published in early 2014 the position paper on the use
of biosimilars in rheumatic conditions, after a natio nal
meeting where the results of two systematic literature
reviews were presented and discussed7. Briefly, Por-
tuguese rheumatologists decided that: i) factors other
than economic should be considered when starting
bio logical therapies; ii) automatic substitution was not
acceptable; iii) switching should be based on the at-
tending physician decision and only after 6 months of
treatment and adequate patient information; and iv)
extrapolation to conditions or patient populations not
studied during the clinical evaluation of a biosimilar
candidate should not be performed7. 
This was the first position paper of a Portuguese
medical society on the use of biosimilars. The concept
of biosimilarity, the highly complex and regulated de-
velopmental process and the implications of using
biosimilars in everyday practice were new to most
rheumatologists. Even so, important statements on
controversial matters were made in a time of limited
trial data and nonexistent daily life clinical experience.
In the past years, this reality has changed: the imple-
mentation of CT-P13 (Remsima®/Inflectra®) in Portu-
gal has grown slowly, but steadily; reports from other
countries on biosimilar use, interchangeability and ex-
trapolation have been released; several observational
studies have been published on the safety in rheuma -
tic and non-rheumatic conditions; and five new anti-
-rheumatic biosimilars were approved in Europe (but
only two by the time our literature review was per-
formed): etanercept (ETN) biosimilars SB4 (Benepali®)
and GP2015 (Erelzi®), INF biosimilar SB2 (Flixabi®),
rituximab biosimilar CT-P10 (Truxima®) and lastly
adalimumab biosimilar ABP 501 (Amgevita®/Solym-
bic®). For these reasons, the Portuguese Society of
Rheumatology considered timely to update the posi-
tion paper on the use of biosimilars in rheumatic pa-
tients.
MAterIAl And Methods
The update of the position paper of the Portuguese So-
ciety of Rheumatology on the use of biosimilars was
based on evidence in the literature and on expert opi -
nion. Six fellows (AS, FT, DJ, TMR, PM, CT) performed
literature searches on biosimilar relevant topics, name-
ly efficacy, safety and immunogenicity, interchangea -
bility, extrapolation of clinical indications, automatic
substitution and pharmacovigilance. Clinical studies
on rheumatic patients, including randomized con-
trolled trials (RCTs), long-term extensions (LTE) and
observational studies were searched in the Medline
database from 2013 to November 2016; evidence pre-
vious to 2013, used to support the 2014 position pa-
per, was also considered. Studies on patients with
dermatologi cal or gastrointestinal conditions were as-
sessed when relevant. Position statements of scienti fic
societies, pharmaceutical industry and patient associa -
tions were hand searched.
The search results were presented to the Portuguese
rheumatologists in an open meeting held in December
2016. Evidence was presented and discussed, and each
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of the 2014 position statements was reviewed and re-
formulated when appropriate. 
PosItIon stAteMents
The updated statements can be found below, followed by
the supporting evidence and experts’ opinion. Table I
presents a glossary of biosimilar-related terms for a bet-
ter understanding of the discussion, and Tables II (En-
glish version) and III (Portuguese version) summarize
the updated statements. 
druG selectIon 
– In a patient starting any biological therapy, treatment
choice should be based on individual, disease and
drug-related factors, and not only on economic as-
pects.
– Whenever the physician chooses to prescribe a bio-
logical drug with an available biosimilar version, the
more affordable drug should be used.
All biosimilars currently approved in the European
Union have demonstrated a high degree of similarity to
their reference products on a quality, non-clinical and
clinical level, the latter in phase I and III RCTs assess-
ing efficacy, safety and immunogenicity. The clinical ef-
ficacy of INF biosimilar CT-P13 (Remsima®/Inflectra®)
was supported by the results of the phase I trial PLA -
NETAS8 in patients with ankylosing spondylitis (AS)
and the phase III trial PLANETRA in patients with
rheumatoid arthritis (RA)9. These studies demonstra ted
that CT-P13 has comparable efficacy to reference INF
up to week 54. Two phase III trials have shown com-
parable efficacy of INF biosimilar SB2 and ETN
biosimi lar SB4 to their respective reference products
up to 54 weeks, in patients with moderate to severe RA
despite methotrexate therapy10-12. CT-P13, SB2 and SB4
have also shown similar positive effects on radiographic
progression in RA, comparing to their reference pro -
ducts9,11,13.
All safety outcomes, including treatment-related ad-
verse events, serious adverse events, serious infections,
discontinuations due to adverse events, malignancies
and deaths, were similar between CT-P13, SB2 and SB4
tAble I. GlossAry of bIosIMIlAr-relAted terMs
Terms Definition
Biosimilar product Biosimilars are biological medicinal products containing a version of the active substance of an
already authorized original biological (reference product), approved after extensive stepwise
comparability following rigorous regulatory frameworks.
Reference A biological product that was approved on the basis of a full data package (registration file).
biological product Reference products are used as the comparators in head-to-head studies to show similarity in
terms of quality, non-clinical and clinical studies of biosimilar products.
Comparability The scientific evaluation of a comparison between a biosimilar candidate and a reference product 
exercise to determine significant differences at a preclinical or clinical level.
Extrapolation of Extrapolation occurs whenever a clinical indication of a reference drug is granted to the biosimilar 
clinical indications without the requirement for clinical studies to support that indication. It relies on an extensive
quality and preclinical assessment followed by an abbreviated clinical phase, performed in a
patient population sensitive enough to detect differences between biosimilar candidate and
reference product. 
Interchangeable An interchangeable biosimilar product can be defined as a biological drug that has demonstrated
biosimilar product biosimilarity to a reference product and when administered to a patient alternating with the
reference product does not compromise safety or efficacy.
Non-medical switch The switch between two biological products due to reasons other than efficacy or safety. The main
driver for non-medical switch is economical, aiming at cost-containment.
Automatic Legal determination allowing pharmacists or other health professionals to switch a biological 
substitution product to a biosimilar version (or vice-versa) without consulting the prescribing physician.
Immunogenicity The ability of a substance to trigger an immune response or reaction (e.g., development of specific
antibodies, T cell response, allergic or anaphylactic reaction).
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and their reference counterparts8-10,12. The only excep-
tion was the lower incidence of injection-site reactions
(3.7% vs 17.5% at 52 weeks) and antidrug antibodies
(1.0% vs 13.2% at 52 weeks) of SB4 compared to refe -
rence ETN12. EMA considered that these differences
didn’t preclude biosimilarity since no apparent corre-
lation between antidrug antibodies and clinical res -
ponse or safety was observed.
During the time between the presentation of the
search results and the publication of this manuscript,
the EMA endorsed three other biosimilars based on
similar efficacy and safety profiles: rituximab and ada -
limumab biosimilars CT-P10 (Truxima®) and ABP 501
(Amgevita®/Solymbic®), respectively, both assessed in
RA patients14,15, and ETN biosimilar GP2015 (Erelzi®),
assessed in patients with plaque-type psoria sis16.
Portuguese rheumatologists understand that the
process leading to the approval of biosimilars in Eu-
rope is highly regulated and allowed new and more
affor dable versions of originator products to enter the
market. Keeping that in mind, they agreed, however,
that the selection of a biological drug to use in a patient
unresponsive or intolerant to conventional treatment is
complex and should take into consideration patient,
disease and drug-related factors. The attending
rheumatologist decides on the biological drug to pres -
cribe considering efficacy, safety and cost-effectiveness
in a case-by-case scenario, supported by a risk-benefit
assessment and individual clinical reasoning (age, co-
morbidities, infectious risk, concomitant treatments
and functional status, among many others). On the 
other hand, it is also the rheumatologist’s responsibili-
ty to strive for the sustainability of healthcare systems.
This means that whenever two or more versions of the
same biological drug are available, the more affordable
should preferably be used, except when the rheuma-
tologist considers that patient, disease or drug-related
factors dictate otherwise.
extrAPolAtIon of clInIcAl IndIcAtIons 
– The extrapolation of clinical indications approved
according to the current European Regulations is ac-
tAble II. PosItIon stAteMents of the PortuGuese socIety of rheuMAtoloGy on the use of
bIosIMIlArs In rheuMAtIc condItIons (enGlIsh versIon)
Biosimilar topic Position Statement
Drug selection In a patient starting any biological therapy, treatment choice should be based on individual, disease
and drug-related factors, and not only on economic aspects.
Whenever the physician chooses to prescribe a biological drug with an available biosimilar
version, the more affordable drug should be used.
Extrapolation of The extrapolation of clinical indications approved according to the current European Regulations 
clinical indications is acceptable.
All biosimilars used in extrapolated indications should be the object of rigorous registry to serve
pragmatical scientific comparisons.
Interchangeability Interchangeability, understood as the similarity between biosimilars to a level that allows the
indistinctive use and change between products in the same patient, cannot be established on the
basis of currently available evidence and thus is not acceptable.
Automatic Automatic substitution of an original biological product for a biosimilar, by either a pharmacist 
substitution and or by legal determination, without information and consent of the attending rheumatologist, is 
non-medical switch unacceptable.
However, judicious switching for a more affordable biological product (non-medical switch) is
desirable, provided that a set of conditions described in the main text is conjunctly met.
Safety, Regulatory authorities, marketing authorization holders (former product license holder) and 
pharmacovigilance healthcare professionals must assure rigorous pharmacovigilance mechanisms.
and traceability The brand name, batch number and date of administration must be registered in the Reuma.pt
database upon every biosimilar drug administration.
If biosimilars have the same INN as the originator molecule, prescription should be performed by
brand name.
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tAble III. PosItIon stAteMents of the PortuGuese socIety of rheuMAtoloGy on the use of
bIosIMIlArs In rheuMAtIc condItIons (PortuGuese versIon)
Tópico Posicionamento
Seleção de fármaco Num doente que inicia tratamento biológico, a escolha do fármaco deve basear-se em factores
relacionados com o indivíduo, com a doença e com o próprio fármaco, e não apenas em factores
económicos.
Sempre que o médico decida prescrever um fármaco biológico que tenha disponível uma versão
biosimilar, o fármaco mais económico deverá ser escolhido.
Extrapolação de A extrapolação de indicações clínicas, aprovadas de acordo com a regulamentação Europeia atual, 
indicações clínicas é aceitável.
Todos os biossimilares utilizados em indicações extrapoladas devem ser objecto de registo rigoroso
para permitir comparações científicas pragmáticas. 
Interpermutabilidade Interpermutabilidade, entendida como a semelhança entre biossimilares a um nível suficiente para
permitir o uso e troca indiscriminados destes produtos no mesmo doente, não pode ser
estabelecida à luz da evidência atual e não é, por isso, aceitável.
Substituição A substituição automática de um biológico original por um biossimilar, por parte do farmacêutico 
automática e switch ou por determinação legal, sem informação e consentimento do reumatologista assistente, é 
não-médico inaceitável.
Contudo, a troca judiciosa por um biológico mais económico (switch não-médico) é desejável,
desde que as condições descritas no texto principal sejam preenchidas na totalidade.
Segurança, As autoridades reguladoras do medicamento, os detentores da autorização de introdução no 
farmacovigilância  mercado e os profissionais de saúde devem garantir mecanismos rigorosos de farmacovigilância.
e rastreabilidade O nome comercial, o número do lote e a data de administração devem ser registados na base de
dados Reuma.pt a cada administração de biossimilar.
Se os biossimilares tiverem a mesma denominação comum internacional que o biológico original, a
prescrição deve ser feita pelo nome comercial.
ceptable.
– All biosimilars used in extrapolated indications
should be the object of rigorous registry to serve
pragmatical scientific comparisons.
Extrapolation of clinical indications is a well-known
scientific principle in manufacturing and licensing of
biological drugs. Extrapolation occurs whenever a
clini cal indication of a reference drug is granted to the
new drug without the requirement for clinical studies
to support that indication, working on the assumption
that if two molecules have similar characteristics and
mechanisms of action their clinical efficacy and safety
will be equivalent5. 
From a regulatory perspective, extrapolation relies
on the extensive quality and non-clinical assessment,
which uses state-of-the-art analytical assays to demons -
trate a high degree of similarity in critical structural and
physicochemical attributes between the biosimilar can-
didate and the originator. This analytical fingerprint is
monitored and tightly controlled throughout the whole
manufacturing process to ensure that similarity remains
within prespecified limits4,17. Biological activi ty is com-
pared using functional tests that should co ver all
known antigen receptor(s) and mechanism(s) of acti -
on of the reference drug in the different clinical indi-
cations, duly justified by a comprehensive literature
search provided by the biosimilar sponsor18. An abbre -
viated clinical phase then follows, in which the spon-
sor selects a patient population sensitive enough to al-
low the detection of possible differences in efficacy,
safety and immunogenicity between biosimilar candi-
date and originator. However, it should be noted that
there is yet no consensus concerning the definition of
the most sensitive population to be used in clinical 
trials of biosimilars, and standards on this matter are
still lacking. As an example, the two currently approved
biosimilars of ETN were assessed in two distinct pa-
tient populations, namely RA (SB4, in Europe) and
plaque psoriasis (GP2015, in the USA). Whenever the
reference drug has distinct clinical indications (for ins -
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tance, cancer and inflammatory rheumatic diseases),
further evidence on functional assays and clinical data
may be required18. In Europe, following the trials in 
AS and RA patients, INF biosimilar CT-P13 was also
approved in psoriatic arthritis (PsA), plaque psoriasis
and adult and pediatric inflammatory bowel disease
(IBD). 
The concept and regulatory framework of extrapo-
lation of clinical indications were well accepted by Por-
tuguese rheumatologists, as they understand that ex-
tensive trials in all clinical indications would lead to
unnecessary and unethical waste of resources and
would compromise the cost-efficiency of biosimilar de-
velopment. In consonance with the EMA requirements,
they emphasize the need for additional data aside from
the standard comparability exercise whenever a
biosimi lar candidate is seeking approval in distinct con-
ditions and patient populations of the reference drug
(different mechanisms of action, pharmacokinetics,
safety and immunogenicity). Despite being reassured
by the inexistence of known safety issues with the
extra polation of previous biosimilars (including CT-
-P13), safety remains of the utmost importance. Por-
tuguese rheumatologists consider that a rigorous phar-
macovigilance plan should be adopted and include fre-
quent efficacy and safety monitoring and registry, for
the purpose of prospective comparisons between orig-
inators and biosimilars.
InterchAnGeAbIlIty 
– Interchangeability, understood as the similarity be-
tween biosimilars to a level that allows the indis-
tinctive use and change between products in the
same patient, cannot be established on the basis of
currently available evidence and thus is not accepta -
ble.
An interchangeable biosimilar product can be de-
fined as a biological drug that has demonstrated
biosimilarity to a reference product and, when admi -
nistered to a patient more than once, alternating be-
tween the reference product and the biosimilar does
not compromise safety or efficacy19. 
Evidence supporting alternation between biosimi-
lar and reference product has, thus far, stemmed from
two types of studies (all including patients with long-
-standing disease): randomized placebo controlled
(non-inferiority) trials and LTE of RCTs. Switching
from INF originator to CT-P13 has been evaluated in a
large (N=481), non-inferiority RCT (NOR-SWITCH)20.
Patients with inflammatory systemic diseases (inclu -
ding RA, spondyloarthritis and PsA) with stable treat-
ment with originator INF for ≥ 6 months were ran-
domized to maintain treatment with the originator INF
or switch to CT-P13. The primary endpoint was de-
fined as disease worsening according to disease-spe-
cific outcomes and/or a consensus between investiga-
tor and patient leading to major change in treatment.
The study, powered to detect a 15% non-inferiority
margin in the entire population, has shown no diffe -
rence between the treatment groups for the primary
endpoint (95% CI of group difference after 54 weeks:
-12.7%; 3.9%), thus supporting non-inferiority for
those switching to CT-P13. However, in possibly un-
derpowered subgroup analyses within each disease-
-groups, the non-inferiority margin was not achieved.
The EGALITY study, a 52-week RCT, compared the
ETN biosimilar candidate GP2015 to originator ETN in
patients with moderate to severe chronic plaque-type
psoriasis16. This is the only study comparing a multi-
ple-switch strategy. After the initial 12-week parallel-
-group period, patients changed treatment for 3 times
in 6-week intervals or maintained treatment with the
original allocated drug. After 52 weeks the maintenance
arms have shown no efficacy or safety differences as
compared to the multiple-switch arms.
In a phase 3 study of the INF biosimilar candidate
SB2 in RA patients, after the initial 54-week parallel-
-group period, the INF arm was re-randomized to ei-
ther maintain INF or switch to SB2, while the SB2 arm
was kept on SB2, up to week 70. This study showed
similar efficacy, safety and immunogenicity results be-
tween the 3 arms21. 
Three open-label LTE (two on CT-P1322, 23 and one
on SB424) in patients with RA and AS compared treat-
ment switch from originator to biosimilar with biosimi -
lar maintenance without randomized treatment re-al-
location, showing no significant differences in efficacy
and safety between treatment-arms. 
Taken altogether, the available evidence, though sug-
gesting that interchangeability may be feasible in pa-
tients with longstanding disease, is yet scarce and not
without bias, thus insufficient to support a positive re -
commendation. Issues were raised on study design,
lack of standards to assess interchangeability and con-
sequences of multiple switches between originators and
biosimilars and biosimilars themselves. More data
stemming from RCTs in well-defined populations,
preferably with multiple and bi-directional switches
from originators and biosimilars, were considered
nece ssary.
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AutoMAtIc substItutIon And non-MedIcAl
swItch
– Automatic substitution of an original biological pro -
duct for a biosimilar, by either a pharmacist or by le-
gal determination, without information and consent
of the attending rheumatologist, is unaccepta ble.
– However, judicious switching for a more affordable
biological product (non-medical switch) is desirable,
provided that a set of conditions described in the
main text is conjunctly met.
Automatic substitution consists in a legal determi-
nation allowing pharmacists or other health profes-
sionals to switch a biological product to a biosimilar
version without consulting the prescribing rheumatolo -
gist. This principle is considered unacceptable by Por-
tuguese rheumatologists. However, there is currently
no clinical reason to prefer a reference product over its
biosimilars approved for the same disease, provided
that similarity is demonstrated according to the EMA
standards. The choice for the most affordable product
should be the rule as an ethical imperative for society,
as long as equal benefit and risk for the patient are assu -
red. As previously mentioned in the Drug Selection
statement, there was agreement in this matter regar -
ding biological treatment initiation. However, in
rheumatic patients already in stable biological treat-
ment, this question is more complex. The switch of the
reference biological to a biosimilar (or vice versa) due
to reasons other than efficacy or safety is known as non-
-medical switch. The main driver for non-medical
switch is economical, aiming at cost-containment.
However, in exceptional cases, the option for a particu -
lar biologi cal product, either the reference biological
or its approved biosimilars, may be warranted owing to
particu lar circumstances of the patient. This decision
can only be made by the rheumatologist. These
exceptio nal circumstances must be clearly documen ted
in order to facilitate the standardization and stream-
lining of these procedures.
For the sake of pharmacovigilance, it is important to
continue monitoring all biological products. Studies
carried out so far are reassuring, but they do not pro-
vide absolute and definitive guarantees that discrepan-
cies do not become apparent over time (especially on
long-term safety). It is an ethical imperative, for physi-
cians and health authorities, to increase the knowledge
in this matter. For this reason it is indispensable to as-
sure traceability of drugs and batches used. Each new
drug should be administered during a sufficient time
period to allow its “pharmacovigilance” (interchanging
between biological products, even biosimilars, in the
same patient, constitutes a potential untraceable safe-
ty risk and an ethically unacceptable loss of opportu-
nity to increase knowledge in this field) and when a
non-medical switch is made, the clinical status of the
patient should be accurately documented (blood sam-
ple collection for biological characterization should be
performed whenever feasible). Every time a non-me -
dical switch occurs, the rheumatologist should be in-
volved in the process.
The judicious switch of a biological product for a
more affordable biosimilar is desirable, provided that
the all following conditions are strictly observed and
complied:
A. Biosimilars must have been approved for the di -
sease under consideration. Only biosimilars
appro ved for the concerning disease, either by direct
assessment or extrapolation of indications, may be
switched.
B. Traceability
B.1. Registration: Official records must be kept of
which product is administered, through its unique
name (trade name if it has the same International
Nonproprietary Name [INN]) and batch number.
B.2. Permanence in therapy: a new product can
only be started if there is guarantee that it will be
available for that patient for the following 12
months.
C. Standardized protocol
C.1. Defined exceptions: consensual definition,
with participation of rheumatologists, of the condi-
tions that may justify the physician’s objection to
non-medical switching.
C.2. Prior notification: The attending rheumatolo-
gist should be involved in the non-medical swi -
tching process and required to issue a clinical report
(des cribed in the next point) that supports his deci-
sion to oppose or approve this switching, in the face
of consensual exceptions.
C.3. Clinical and Biological Registry: Non-medi-
cal switching is obligatorily preceded by a detailed
and protocoled clinical record made by the rheuma-
tologist at the Rheumatic Diseases Portuguese Re -
gistry, Reuma.pt. The administration of the new
product is ideally preceded by a blood sample col-
lection and storage in a biobank.
C.4. Conflict resolution: The objection of a rheu -
matologist to non-medical switching shall, in all ca -
ses, be submitted to the approval of the Pharmacy
and Therapeutics Committee of the hospital or
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in Reuma.pt when the patient is treated in the day care
unit. As the majority of rheumatic patients are treated
as outpatients, the rheumatologist has no access to the
biosimilar batch number, and thus the hospital phar-
macist should be responsible for registering that infor-
mation. 
The approval of various biosimilars for the same
refe rence product increases the likelihood of a misat-
tribution of an adverse event, so biosimilar nomencla-
ture is key. According to EMA guidelines, correct na -
ming of biological drug should include the brand name
or the INN together with a trademark30. Portuguese
rheumatologists were also in agreement with this re -
commendation.
conclusIon
The 2017 update of the Portuguese Society of Rheuma-
tology position paper on the use of biosimilars con-
venes both expert opinion and evidence gathered since
the publication of the first paper. Portuguese rheuma-
tologists considered that affordability should be taken
into consideration when prescribing a biological drug
for the first time, but other patient- and disease-rela ted
factors were deemed equally important. In patients al-
ready on biological treatment with a reference pro duct,
switch for a more affordable biosimilar was also desi -
rable, provided a set of conditions was rigorously met.
Automatic substitution was considered not acceptable
and current evidence is insufficient to support inter-
changeability. Extrapolation of clinical indications was
endorsed by Portuguese rheumatologists, provided that
European regulations were followed. The statements
on safety, pharmacovigilance and traceability were in
accordance with the previous paper. 
With this position paper, the Portuguese Society of
Rheumatology reinforces its role as a key stakeholder
in the quality of care of Portuguese rheumatic patients,
striving for more affordable and more accessible bio-
logical treatments, but keeping as a priority the patient’s
best interest. 
conflIct of Interests
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C.5. Patient information: The patient must be in-
formed before non-medical switching.
sAfety, PhArMAcovIGIlAnce And 
trAceAbIlIty 
– Regulatory authorities, marketing authorization
holders (former product license holder) and health-
care professionals must assure rigorous pharma-
covigilance mechanisms.
– The brand name, batch number and date of admi -
nistration must be registered in the Reuma.pt
database upon every biosimilar drug administration.
– If biosimilars have the same INN as the originator
molecule, prescription should be performed by
brand name.
As mentioned above, the safety of biosimilar candi-
dates has been highly similar to their reference pro -
ducts during the stepwise comparability exercise re-
quired for approval8-10,12. Nevertheless, the clinical con-
firmatory phase of biosimilar development is per-
formed in a limited patient population, during a limited
follow-up and only in one (or just a few) clinical indi-
cation(s) of the reference product. This means that ro-
bust pharmacovigilance plans are of the utmost im-
portance to assure that the comparable safety profile in
clinical trials persists in everyday practice, and all stake-
holders should be involved. Methods of pharmacovi -
gilance include passive methods, such as spontaneous
reporting systems, active surveillance, such as elec-
tronic healthcare databases, comparative observatio nal
studies and targeted clinical investigations25. The dif-
ferent existing national registries have proved to effec-
tively monitor patients with rheumatic diseases on bio -
logicals26,27. Since 2008, Reuma.pt presents as an es-
sential tool for pharmacovigilance and traceability of
biological-treated patients, and Portuguese rheuma-
tologists consider that its use should also be applied in
biosimilar-treated patients. 
As part of the pharmacovigilance strategy, effective
drug traceability is warranted so that timely detection
of safety issues and appropriate intervention are en-
sued18, 28. The pharmaceutical supply chain of biologi-
cals contains several steps of potential incomplete trac-
ing, namely in medical prescription, pharmacy dis-
pensing and biological administration. In a cross sec-
tional study, the batch number was reported along with
the drug name in only 19.9% of all biopharmaceutical
drug reports29. It is feasible and advisable for the at-
tending rheumatologist to register the batch number
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dual opinions or the adopted position statements, which were col-
lectively endorsed. Pharmaceutical companies had no direct or in-
direct intervention in the elaboration of this Position Paper.
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